Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00146211 · ClinicalTrials.gov registry record · Phase 3
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
A Phase 3 study of Huntington Disease, sponsored by Amarin Neuroscience.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT00146211: Completed Phase 3 study of Huntington Disease, sponsored by Amarin Neuroscience.
NCT00146211 is a Phase 3 study of Huntington Disease that has completed, run by Amarin Neuroscience. The registered enrollment target is 300 participants, below the 627-participant average among 35 other Huntington Disease trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00146211, a Phase 3 study of Huntington Disease, has completed, sponsored by Amarin Neuroscience.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to determine the effect of 2 gram/day of ethyl-EPA on motor (movement) signs and symptoms of Huntington disease.
Conditions Studied
Interventions
- DRUG Ethyl-EPA (Miraxion™)
Study Locations (20)
California
- University of California San Diego - La Jolla
- UCLA Medical Center - Los Angeles
- University of California Davis - Sacramento
- University of California San Francisco - San Francisco
Florida
- University of Florida - Gainesville
- University of Miami - Miami
- University of South Florida - Tampa
Georgia
- Emory University - Atlanta
- Medical College of Georgia - Augusta
Illinois
- Rush University Medical Center - Chicago
- University of Chicago - Chicago
Kansas
- University of Kansas - Kansas City
- Hereditary Neurological Disease Centre - Wichita
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic Arizona - Scottsdale
Colorado
- Colorado Neurological Institute - Englewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
What the finished NCT00146211 record still lists
NCT00146211 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 627-participant average among 35 other Huntington Disease trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 1 intervention - of which Ethyl-EPA (Miraxion™) is the first listed.
NCT00146211 names 20 study sites across 12 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00146211 about?
NCT00146211 is a clinical study titled "TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease". This study is designed to determine the effect of 2 gram/day of ethyl-EPA on motor (movement) signs and symptoms of Huntington disease.
What is the current status of trial NCT00146211?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2005-09. Estimated completion is 2007-07.
What conditions does trial NCT00146211 study?
This clinical trial studies the following conditions: Huntington Disease.
What interventions are being tested in trial NCT00146211?
The interventions under investigation include: Ethyl-EPA (Miraxion™) (DRUG).
Who is sponsoring clinical trial NCT00146211?
This trial is sponsored by Amarin Neuroscience, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00146211 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00146211's enrollment target sits among peer trials
300 12th of 35 higher than 24 of 35 other Huntington Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
RECRUITING · Phase 3
-
A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease
COMPLETED · Phase 3
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Longitudinal Endpoint Assessment of Disease Burden in HD
RECRUITING
-
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
RECRUITING
-
Extracellular Vesicles for HD
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia